Related Experiment Video
Updated: May 15, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Clinician perceptions of asynchronous care for patients with ovarian cancer on PARP inhibitor therapy
Melissa Kozak1, Ainhoa Madariaga2, Yuliya Gavrylyuk1
1University Health Network, Princess Margaret Cancer Centre, Cancer Digital Intelligence (CDI), Toronto, Canada; Techna, University Health Network, Toronto, Canada.
Abstract:
Asynchronous care is an alternative model of care involving information transmission without a simultaneous interaction between people. This study aimed to understand clinician perspectives about providing asynchronous care to patients with ovarian cancer who are clinically stable and receiving poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) maintenance therapy at a large academic teaching hospital. The Theoretical Domains Framework (TDF) was used to undertake this study. Interviews were conducted with oncologists, physician assistants, and nurses who actively manage this patient population. Data were analyzed according to TDF domains to generate themes and understand supports, barriers, and buy-in related to this model of care. Overall, 73% of the 15 clinicians (50% of the oncologists) participating in this study were willing to provide asynchronous care to patients on PARPi who were clinically stable. Several themes emerged representing considerations for moving forward with this model of care, including selecting the ideal patients, streamlined access to information, safe and effective escalations, perceived acceptability of the asynchronous model by clinicians, reimbursement, and an opportunity and willingness to innovate. Participants recognized the potential benefits of an asynchronous care model for patients on PARPi therapy who are clinically stable and the opportunity to innovate while optimizing the use of limited clinic resources. Continued work toward discovery and implementation of an asynchronous care model should account for findings uncovered by application of the TDF.
Related Concept Videos
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Patient-centered Care
Continuing Care

